« Return to News | Awards & Advancement

Merrimack raises $77 million for cancer therapeutics

Thursday, April 14, 2011 12:26 PM

Massachusetts-based Merrimack Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of treatments for cancer, has raised $77 million in a Series G private financing with participation by new and existing investors. Proceeds from the financing will be used to advance the company’s pipeline cancer therapeutics, according to Fierce Biotech. 

Some of the company’s most advanced product candidates are MM-398, a nanoliposomal formulation of irinotecan, currently in three phase II trials, MM-121, an ErbB3 antagonist, currently in four phase I/II trials, and MM-111, a bispecific antibody targeting ErbB2/ErbB3, currently in three phase 1/II trials.

"Over the last 10 years, our investors have been a critical force to help us build a biopharmaceutical company based on a systems approach to drug discovery and development," said Robert Mulroy, president and chief executive officer. "We are excited to add more quality investors who are aligned with our vision to create transformative medicines and diagnostics to benefit cancer patients everywhere."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.